Target intelligence / Profile preview

Protein tyrosine phosphatase non-receptor type 3 (PTPN3)

Target
PTPN3
Molecular classification
Enzyme, Protein tyrosine phosphatase, Non-receptor phosphatase
01

Overview

Protein tyrosine phosphatase non-receptor type 3 (PTPN3) is a multidomain enzyme in the protein tyrosine phosphatase (PTP) family containing FERM, PDZ, and catalytic domains. It regulates a broad range of cellular processes, including cell growth, differentiation, mitosis, and immune signaling, through dephosphorylation of tyrosine residues on target proteins. PTPN3 can function as either a tumor suppressor or promoter, depending on cellular context and disease state, and is involved in the regulation of receptor and ion channel activity, growth hormone signaling, and immune cell function. It interacts with cellular and viral proteins, such as the E6 oncoproteins from high-risk human papillomavirus (HPV16/18) and hepatitis B virus (HBV), via its PDZ domain, which is also implicated in controlling its enzymatic activity through autoinhibition. Dysregulation or mutation of PTPN3 is associated with tumorigenesis in various cancers, and its modulation by viral oncoproteins has implications for both cancer development and viral pathogenesis.

Other names
Tyrosine-protein phosphatase non-receptor type 3PTPH1PTP-H1Protein-tyrosine phosphatase H1Cytoskeletal-associated protein tyrosine phosphatase
02

Mechanism of action

Inhibitors or modulators would work via inhibition of phosphatase activity or disruption of protein-protein interactions (e.g., via PDZ domain interactions with cellular or viral PBM motifs)

03

Biological functions

Signal transductionRegulation of cell growthDelineationMitotic cycle regulationOncogenic transformationImmune signaling modulation (including dephosphorylation of T cell receptor components)Cytoskeletal association
04

Disease associations

Cancer (tumor suppression or promotion, context dependent)Infection (interacts with HPV and HBV viral proteins)Oncogenesis in various tumor types (e.g., cholangiocarcinoma, prostate cancer, breast cancer)
05

Safety considerations

Dual role in oncogenesis (can act as tumor suppressor or promoter contextually), implying risk of adverse effects if targeted without specific contextPotential for effects on immune signaling and cell growth if misregulated or broadly inhibited
06

Biomarkers

PTPN3 expression levels could serve as a biomarker for certain cancers (e.g., perihilar cholangiocarcinoma, breast cancer) and are modulated in response to viral infection or therapeutic intervention

Beyond the preview

Go deeper on Protein tyrosine phosphatase non-receptor type 3 (PTPN3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein tyrosine phosphatase non-receptor type 3 (PTPN3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call